|
FY2025
12 months to Aug 31, 2025
|
FY2024
12 months to Aug 31, 2024
|
FY2023
12 months to Aug 31, 2023
|
|
|---|---|---|---|
| Operating activities | |||
| Net loss for the year | |||
| Adjustments for the following non-cash items: | |||
| Depreciation of property and equipment | |||
| Depreciation of intangible assets | |||
| Amortization of intangible assets | |||
| Depreciation on right of use asset | |||
| Bad debts written off | |||
| Interest expense on lease liability | |||
| Write down of investment | |||
| Loss on derecognition of right of use of asset | |||
| Accretion expense | |||
| Loss on extinguishment of liability | |||
| Gain (loss) on change in fair value of the conversion feature liability | |||
| Unrealized foreign exchange gain (loss) | |||
| Net changes in non-cash working capital balances: | |||
| Trade and other receivables | |||
| Prepaid expenses and deposits | |||
| Accounts payable and accrued liabilities | |||
| Deferred government incentive | |||
| Deferred revenue | |||
| Income taxes receivable | |||
| Net cash used in operating activities | |||
| Financing activities | |||
| Share capital issuance | |||
| Loan from directors | |||
| Exercise of share warrants | |||
| Warrant liability allocation on share capital issuance | |||
| Share issue cost | |||
| Proceed from conversion note | |||
| Proceed from equity purchase agreement | |||
| Proceed from scientific research and development loan | |||
| Repayment of scientific research and development loan | |||
| Repayment of lease obligations | |||
| Net cash provided by financing activity | |||
| Investing activities | |||
| Additions to intangible assets | |||
| Additions to property and equipment | |||
| Net cash used in investing activity | |||
| Net change in cash | |||
| Effect of changes in foreign exchange rates | |||
| Cash, beginning of year | |||
| Cash, end of year | |||
| Interest paid |
Loading...
